Search Results - "Letocha, H"

2130 Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab + FOLFIRI by Karthaus, M, Hofheinz, R, Mineur, L, Letocha, H, Greil, R, Thaler, J, Fernebro, E, Zhang, Y, Oliner, K.S, Demonty, G, Kohne, C.H

Get full text

Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer by Albertsson, M, Johansson, B, Friesland, S, Kadar, L, Letocha, H, Frykholm, G, Wagenius, G

“…The purpose of these studies was to compare efficacy and toxicity of docetaxel alone with the combination of gemcitabine and docetaxel for treatment of…”
Get full text

76 Support group intervention after breast cancer treatment: first results of a prospective randomized study by Björneklett, H. Granstam, Lindemalm, C, Ojutkangas, M.L, Letocha, H, Strang, P, Bergkvist, L

Get full text

6073 Interim analysis of epidermal-growth factor receptor (EGFR) expression in a single-arm, phase II, first-line study (20060314) of panitumumab with FOLFIRI in the management of metastatic colorectal cancer (mCRC) by Koehne, C, Hofheinz, R, Mineur, L, Letocha, H, Greil, R, Thaler, J, Gamelin, E, Fernebro, E, Wright, L, Karthaus, M

Get full text

Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair by Tarish, Firas L, Schultz, Niklas, Tanoglidi, Anna, Hamberg, Hans, Letocha, Henry, Karaszi, Katalin, Hamdy, Freddie C, Granfors, Torvald, Helleday, Thomas

“…Chemical castration improves responses to radiotherapy in prostate cancer, but the mechanism is unknown. We hypothesized that this radiosensitization is caused…”
Get more information

Positron emission tomography in the diagnosis and staging of urinary bladder cancer by Ahlström, H, Malmström, P U, Letocha, H, Andersson, J, Långström, B, Nilsson, S

“…Evaluation of positron emission tomography (PET) using (18)fl 18F-2-fluoro-2-deoxy-D-glucose (18FDG) and L-methyl-11C-methionine in the diagnosis and staging…”
Get more information

Abstract P2-12-09: A randomized controlled trial of support group intervention after breast cancer treatment: Results on sick leave, health care utilization and health economy by Granstam, Björneklett H, Rosenblad, A, Lindemalm, C, Ojutkangas, M-L, Letocha, H, Strang, P, Bergkvist, L

“…Abstract Background: More than 50% of breast cancer patients are diagnosed before the age of 65. Returning to work after treatment is, therefore, of interest…”
Get full text

Long-term follow-up of a randomized study of support group intervention in women with primary breast cancer by Björneklett, Helena Granstam, Rosenblad, Andreas, Lindemalm, Christina, Ojutkangas, Marja-Leena, Letocha, Henry, Strang, Peter, Bergkvist, Leif

“…Abstract Background Despite a fairly good prognosis, many breast-cancer patients suffer from symptoms such as anxiety, depression and fatigue, which may affect…”
Get full text

PD04-06: A Randomised Controlled Trial of Quality of Life and Fatigue after Support Group Intervention in Primary Breast Cancer Patients by Granstam Björneklett, H, Lindemalm, C, Ojutkangas, M-L, Berglund, A, Letocha, H, Strang, P, Bergkvist, L

“…Abstract Background: When diagnosed with breast cancer, most women's lives change as well as their perspectives on and appreciation of life. The aim of the…”
Get full text

A randomised controlled trial of support group intervention after breast cancer treatment: results on anxiety and depression by Björneklett, Helena Granstam, Lindemalm, Christina, Rosenblad, Andreas, Ojutkangas, Marja-Leena, Letocha, Henry, Strang, Peter, Bergkvist, Leif

“…Previous studies have demonstrated that between 20 and 30% of women treated for breast cancer have measurable signs of anxiety and depression compared with 6%…”
Get more information

A randomized controlled trial of a support group intervention on the quality of life and fatigue in women after primary treatment for early breast cancer by Björneklett, Helena Granstam, Lindemalm, Christina, Ojutkangas, Marja-Leena, Berglund, Anders, Letocha, Henry, Strang, Peter, Bergkvist, Leif

“…Background When diagnosed with breast cancer, most women’s lives change as well as their perspectives on and appreciation of life. The aim of the present study…”
Get full text

The relationship between quality of life (QoL) and tumor response in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab (pmab) plus FOLFIRI as first-line therapy: An analysis of study 314 by Karthaus, M., Thaler, J., Hofheinz, R., Mineur, L., Letocha, H., Greil, R., Fernebro, E., Gamelin, E., Baños, A., Kohne, C.

“…Abstract only…”
Get full text

A randomized controlled trial of support group intervention after breast cancer treatment: results on sick leave, health care utilization and health economy by Björneklett, Helena Granstam, Rosenblad, Andreas, Lindemalm, Christina, Ojutkangas, Marja-Leena, Letocha, Henry, Strang, Peter, Bergkvist, Leif

“…More than 50% of breast cancer patients are diagnosed before the age of 65. Returning to work after treatment is, therefore, of interest for both the…”
Get more information

Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Resections and curative surgery in a phase II single arm, multicenter study (20060314) by Hofheinz, R., Mineur, L., Greil, R., Kohne, C., Letocha, H., Thaler, J., Fernebro, E., Gamelin, E., DeCosta, L., Karthaus, M.

“…Abstract only…”
Get full text

A phase I/II study (TaxXel) on the treatment with docetaxel in combination with capecitabin in patients with metastatic esophageal cancer or cancer in the cardia region by Friesland, Signe, Wickart-Johansson, Gun, Kadar, Lianna, Bratthall, Charlotte, Letocha, Henry, Franzen, Lars, Jacobsen, Anne-Birgitte, Weber Hauge, Petra, Wagenius, Gunnar, Hatlevoll, Ingunn, Glenjen, Nils

“…Abstract only e14531 Background: This is an open label, non-randomized, multicenter phase I-II study with Docetaxel (Doc) given in combination with…”
Get full text

Epidermal growth factor receptor (EGFR) inhibitor–related skin toxicity: Review of interim data from a phase II study (20060314) of panitumumab (pmab) with FOLFIRI in the first-line treatment of metastatic colorectal cancer (mCRC) by Karthaus, M., Hofheinz, R., Mineur, L., Letocha, H., Greil, R., Thaler, J., Gamelin, E., Wright, L., Köhne, C.

“…Abstract only e20634 Background: Skin toxicity that can impact quality of life as well as treatment adherence is commonly associated with EGFR therapy. Despite…”
Get full text

Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC) by Greil, R., Letocha, H., Gamelin, E., Thaler, J., Hofheinz, R., Mineur, L., Fernebro, E., Karthaus, M., Wright, L., Köhne, C.

“…Abstract only 4085 Background: The fully human anti-epidermal growth factor receptor monoclonal antibody pmab, has proven monotherapy activity in chemotherapy…”
Get full text

A randomized controlled trial of support group intervention after breast cancer treatment: Results on sick leave, health care utilization and health economy by Granstam, BH, Rosenblad, A, Lindemalm, C, Ojutkangas, ML, Letocha, H, Strang, P, Bergkvist, L

Get full text

An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer by Berglund, Åke, Byström, Per, Johansson, Birgitta, Nygren, Peter, Frödin, Jan-Erik, Pedersen, Dorte, Letocha, Henry, Glimelius, Bengt

“…The feasibility, safety, and efficacy of planned sequential administration of docetaxel and irinotecan with 5-fluorouracil (5-FU)/leucovorin in advanced upper…”
Get full text

The efficacy of preoperative systemic chemotherapy in the local control of muscle-invasive transitional cell carcinoma of the urinary bladder by Letocha, H S, Malmström, P U, Busch, C, Nilsson, S

“…Transitional cell carcinoma of the urinary bladder has a poor prognosis, once the muscle layers of the bladder wall have been invaded, irrespective of whether…”
Get more information